Influence of chalcone analogues on serum glucose levels in hyperglycemic rats

Chemico-Biological Interactions

Volumn 171, Issue 3, 2008, Pages 355-362

  Alberton, Elga Heloísa ^a   Damazio, Rosangela Guollo ^a   Cazarolli, Luisa Helena ^a   Chiaradia, Louise Domeneghini ^a   Leal, Paulo César ^a   Nunes, Ricardo José ^a   Yunes, Rosendo Augusto ^a   Silva, Fátima Regina Mena Barreto ^a  

^a FEDERAL UNIVERSITY OF SANTA CATARINA   (Brazil)

Author keywords

Analogues; Chalcone; Hyperglycemia; Insulin; Tolbutamide

Indexed keywords

CHALCONE DERIVATIVE; GLUCOSE;

ARTICLE; CONTROLLED STUDY; DRUG ACTIVITY; DRUG EFFECT; DRUG INHIBITION; DRUG STRUCTURE; HYPERGLYCEMIA; MALE; NONHUMAN; NUCLEAR MAGNETIC RESONANCE SPECTROSCOPY; RAT;

ADMINISTRATION, ORAL; ANIMALS; BLOOD GLUCOSE; CHALCONE; DISEASE MODELS, ANIMAL; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG EVALUATION, PRECLINICAL; GLUCOSE; HYPERGLYCEMIA; HYPOGLYCEMIC AGENTS; INSULIN; MALE; MOLECULAR STRUCTURE; RATS; RATS, WISTAR; STEREOISOMERISM; TIME FACTORS; TOLBUTAMIDE;

ANIMALIA; RATTUS;

EID: 38549176079     PISSN: 00092797     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.cbi.2007.11.001     Document Type: Article

References (34)

1. O'Brien R.M., and Granner D.K. Regulation of gene expression by insulin. Physiol. Rev. 76 (1996) 1109-1161
2. American Diabetes Association. Diagnosis and classification of diabetes mellitus. Diabetes Care 29 (2006) 43-48
3. Concannon P., Erlich H.A., Julier C., Morahan G., Nerup J., Pociot F., Todd J.A., and Rich S.S. Type 1 Diabetes Genetics Consortium, Type 1 diabetes: evidence for susceptibility loci from four genome-wide linkage scans in 1,435 multiplex families. Diabetes 54 (2005) 2995-3001
4. Inzucchi S.E. Oral antihyperglycemic therapy for type 2 diabetes. JAMA 287 (2002) 360-372
5. Gerich J.E. Novel insulins: expanding options in diabetes management. Am. J. Med. 113 (2002) 308-316
6. Banting F.G., Best C.H., Collip J.B., Campbell W.R., and Fletcher A.A. Pancreatic extracts in the treatment of diabetes mellitus. Preliminary report. Can. Med. Assoc. J. 12 (1922) 141-146
7. Henquin J.C. Pathways in β-cell stimulus-secretion coupling as targets for therapeutic insulin secretagogues. Diabetes 53 (2004) 48-58
8. Henquin J.C. The fiftieth anniversary of hypoglycaemic sulphonamides: how did the mother compound work?. Diabetologia 35 (1992) 907-912
9. Zhao L.M., Jin H.S., Sun L.P., Piao H.R., and Quan Z.S. Synthesis and evaluation of antiplatelet activity of trihydroxychalcone derivatives. Bioorg. Med. Chem. Lett. 15 (2005) 5027-5029
10. Valla A., Valla B., Cartier D., Le Guilou R., Labia R., Florent L., Charneau S., Schrevel J., and Portier P. New syntheses and potential antimalarial activities of new "retinoid-like chalcones". Eur. J. Med. Chem. 41 (2006) 142-146
11. Lawrence N.J., Patterson R.P., Ooi L., Cookc D., and Ducki S. Effects of a-substitutions on structure and biological activity of anticancer chalcones. Bioorg. Med. Chem. Lett. 16 (2006) 5844-5848
12. Hsu Y.L., Kuo P.L., Tzeng W.S., and Lin C.C. Chalcone inhibits the proliferation of human breast cancer cell by blocking cell cycle progression and inducing apoptosis. Food Chem. Toxicol. 44 (2006) 704-713
13. Ahmad S., Israf D.A., Lajis N.H., Shaari H.M., Mohamed H., Wahab A.A., Ariffin K.T., Hoo W.Y., Aziz N.A., Kadir A.A., Sulaiman M.R., and Somchit M.N. Cardamonin, inhibits pro-inflammatory mediators in activated RAW 264.7 cells and whole blood. Eur. J. Pharmacol. 538 (2006) 188-194
14. Severi F., Benvenuti S., Costantino L., Vampa G., Melegafi M., and Antolini L. Synthesis and activity of a new series of chalcones as aldose reductase inhibitors. Eur. J. Med. Chem. 33 (1998) 859-866
15. Chen R.M., Hu L.H., An T.Y., Li J., and Shen Q. Natural PTP1B inhibitors from Broussonetia papyrifera. Bioorg. Med. Chem. Lett. 12 (2002) 3387-3390
16. Kamei R., Kadokura M., and Kitagawa Y. 2-benzyloxychalcone derivatives stimulate glucose uptake in 3T3-L1 adipocytes. Life Sci. 73 (2003) 2091-2099
17. Satyanarayana M., Tiwari P., Tripathi B.K., Srivastava A.K., and Pratap R. Synthesis and antihyperglycemic activity of chalcone based aryloxypropanolamines. Bioorg. Med. Chem. 12 (2003) 883-889
18. Silva F.R.M.B., Szpoganicz B., Pizzolatti M.G., Willrich M.A.V., and De Sousa E. Acute effect of Bauhinia forficata on serum glucose levels in normal and alloxan-induced diabetic rats. J. Ethnopharmacol. 83 (2002) 33-37
19. De Sousa E., Zanatta L., Seifriz I., Creczynski-Pasa T.B., Pizzolatti M.G., Szpoganicz B., and Silva F.R.M.B. Hypoglycemic effect and antioxidant potencial of kaempferol-3,7-O-(α)-dirhamnoside from Bauhinia forticata leaves. J. Nat. Prod. 67 (2004) 829-833
20. 14C-glucose uptake in rat soleus muscle. Chem. Biol. Interact. 149 (2004) 89-96
21. Cazarolli L.H., Zanatta L., Jorge A.P., De Sousa E., Horst H., Woehl V.M., Pizzolatti M.G., Szpoganicz B., and Silva F.R.M.B. Follow-up studies on glycosylated flavonoids and their complexes with vanadium: their anti-hyperglycemic potential role in diabetes. Chem. Biol. Interact. 163 (2006) 177-191
22. Zanatta L., De Sousa E., Cazarolli L.H., Junior A.C., Pizzolatti M.G., Szpoganicz B., and Silva F.R.M.B. Effect of crude extract and fractions from Vitex megapotamica leaves on hyperglycemia in alloxan-diabetic rats. J. Ethnopharmacol. 109 (2007) 151-155
23. Yunes R.A., Chiaradia L.D., Leal P.C., Cechinel Filho V., Santos E.C.T., Falcão C.A.B., and Bergmann B.R. Chalcones as new drug leads against Leishmaniasis. Curr. Trends Med. Chem. 4 (2006) 47-56
24. Marais J.P.J., Ferreira D., and Slade D. Stereoselective synthesis of monomeric flavonoids. Phytochemistry 66 (2005) 2145-2176
25. Zareba G., Serradell N., Castañer R., Davies S.L., Prous J., and Mealy N. Phytotherapies for diabetes. Drugs Future 30 (2005) 1253-1262
26. Domínguez J.N., Charris J.N., Lobo G., De Dominguez N.G., Moreno M.M., Riggione F., Sanchez E., Olson J., and Rosenthal P.J. Synthesis of quinolinyl chalcones and evaluation of their antimalarial activity. Eur. J. Med. Chem. 36 (2001) 555-560
27. Monostory K., Tamási V., Vereczkey L., and Perjési P. A study on CYP1A inhibitory action of E-2-(4′-methoxybenzylidene)-1-benzosuberone and some related chalcones and cyclic chalcone analogues. Toxicology 184 (2003) 203-210
28. Rojas J., Payá M., Domínguez J.N., and Ferrándiz M.L. ttCH, a selective inhibitor of inducible nitric oxide synthase expression with antiarthritic properties. Eur. J. Pharmacol. 465 (2003) 183-189
29. Nookandeh A., Frank N., Steiner F., Ellinger R., Schneider B., Gerha C., and Becker H. Xanthohumol metabolites in feces of rats. Phytochemistry 65 (2004) 561-570
30. Piñero J., Temporal R.M., Gonçalves A.J.S., Jiménez I.A., Bazzocchi I.L., Oliva A., Perera A., Leon L.L., and Valladares B. New administration model of trans-chalcone biodegradable polymers for the treatment of experimental leishmaniasis. Acta Trop. 98 (2006) 59-65
31. Shukla P., Singh A.M., Srivastava A.K., and Pratap R. Chalcone based aryloxypropanolamines as potential antihyperglycemic agents. Bioorg. Med. Chem. Lett. 17 (2007) 799-802
32. Nakadate T.O., Aizu E.O., Yamamoto S.O., and Kato R. Effects of chalcone derivatives on lipoxygenase and cyclooxygenase activities of mouse epidermis. Prostaglandins 30 (1985) 357-368
33. Ballesteros J.F., Sanz M.J., Ubeda A., Miranda M.A., Iborra S., Paya M., and Alcaraz M.J. Synthesis and pharmacological evaluation of 2′-hydroxychalcones and flavones as inhibitors of inflammatory mediators generation. J. Med. Chem. 14 (1995) 2794-2797
34. Kim Y.P., Ban H.S., Lin S.S., Kimura N., Jung S.H., Ji J., Lee S., Ryu N., Keum S.R., Shin K.H., and Ohuchi K. Inhibition of prostaglandin E2 production by 2′-hydroxychalcone derivatives and the mechanism of action. J. Pharm. Pharmacol. 53 (2001) 1295-1302